The VEGFR2-targeting TKI cabozantinib was also associated with a reduction in the number of Tregs and MDSCs, and simultaneously promoted tumor infiltration of CD4+ and CD8+ T lymphocytes, both alone and in combination with the anti-cancer vaccine MVA/rF-CEA/TRICOM (65). Here, CD8A is linked to neoplasm.